Immunovant, Inc. (IMVT) has a consensus analyst rating of Buy, based on 23 analysts covering the stock. Of those, 18 recommend buying, 4 recommend holding, and 1 recommend selling.
The analyst consensus price target for IMVT is $35.67, representing a +34.4% upside from the current price of $26.55. Price targets range from a low of $16.00 to a high of $50.00.
